



- (51) **International Patent Classification:**
A61K 31/352 (2006.01) *C07D 263/52* (2006.01)
- (21) **International Application Number:**
PCT/US2013/043016
- (22) **International Filing Date:**
29 May 2013 (29.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/653,321 30 May 2012 (30.05.2012) US
61/782,038 14 March 2013 (14.03.2013) US
- (71) **Applicants:** **ASTELLAS PHARMA INC.** [JP/JP]; 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **COMENTIS, INC.** [US/US]; 280 Utah Avenue, Suite 275, South San Francisco, CA 94080 (US).
- (72) **Inventors:** **MUNAKATA, Ryosuke**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **INOUE, Makoto**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **TOMINAGA, Hiroaki**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **YAMASAKI, Shingo**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **SHIINA, Yasuhiro**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **SAMIZU, Kiyohiro**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **HAMAGUCHI, Hisao**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP). **HONG, Lin**; 15613 Sugar Loaf Drive, Edmond, OK 73013 (US).
- (74) **Agents:** **BOLIN, Kimberly, A.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report (Art. 21(3))*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
 - *with sequence listing part of description (Rule 5.2(a))*
- (88) **Date of publication of the international search report:**
30 January 2014

(54) **Title:** CHROMANE COMPOUNDS

(57) **Abstract:** The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β -secretase activity, hydrolysis of a β -secretase site of a β -amyloid precursor protein, and/or β -amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.

